Filing Details

Accession Number:
0000950170-25-042026
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-19 16:21:04
Reporting Period:
2025-03-17
Filing Date:
2025-03-19
Accepted Time:
2025-03-19 16:21:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
730272 Repligen Corp RGEN Biological Products, (No Disgnostic Substances) (2836) 042729386
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1606030 Anthony Hunt C/O Repligen Corporation
41 Seyon St., Bldg 1, Ste 100
Waltham MA 02453
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-03-17 5,000 $33.87 141,301 No 4 M Direct
Common Stock Acquisiton 2025-03-17 21,756 $59.52 163,057 No 4 M Direct
Common Stock Disposition 2025-03-17 60 $148.05 162,997 No 4 S Direct
Common Stock Disposition 2025-03-17 100 $150.38 162,897 No 4 S Direct
Common Stock Disposition 2025-03-17 2,518 $151.09 160,379 No 4 S Direct
Common Stock Disposition 2025-03-17 6,176 $151.96 154,203 No 4 S Direct
Common Stock Disposition 2025-03-17 15,619 $152.82 138,584 No 4 S Direct
Common Stock Disposition 2025-03-17 2,283 $153.70 136,301 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2025-03-17 5,000 $0.00 5,000 $33.87
Common Stock Stock Option (Right to Buy) Disposition 2025-03-17 21,756 $0.00 21,756 $59.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
202,344 2028-03-01 No 4 M Direct
0 2029-02-28 No 4 M Direct
Footnotes
  1. Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024.
  2. $148.05 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.01 to $148.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. $151.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.42 to $151.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. $151.96 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.43 to $152.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. $152.82 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.39 to $153.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
  6. $153.70 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.55 to $153.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027.
  8. This option is fully vested and exercisable.